# Department of Health and Hospitals Bureau of Health Services Financing

### MEMORANDUM

DATE:

November 25, 2014

TO:

Louisiana Medicaid Providers

FROM:

J. Ruth Kennedy, Medicaid Director

SUBJECT:

Edits on Proton Pump Inhibitors (PPIs) for Louisiana Medicaid Pharmacy Program

Effective December 3, 2014, the Louisiana Medicaid Pharmacy Program in collaboration with the Louisiana Medicaid Drug Utilization Review (DUR) Board has modified the edits on Proton Pump Inhibitors (PPIs).

#### **Diagnosis Codes**

Pharmacy claims for PPIs will still process for payment up to 120 days duration of therapy each fiscal year. Claims for Proton Pump Inhibitors (PPIs) will continue to require a diagnosis code in NCPDP field 424-DO (Diagnosis Code) at Point of Sale (POS) in order to bypass (be exempt from) the duration of therapy edit. The appropriate diagnosis codes have been modified as noted in the table.

Select Diagnosis Codes Which May Justify Long-Term Use of PPIs	
ICD-9-CM Diagnosis Code(s)	Diagnosis Description
202.6-202.68	Malignant Mast Cell Tumors
237.4	Multiple Endocrine Adenomas
251.5	Zollinger-Ellison Syndrome
277.00-277.09	Cystic Fibrosis
530.19	Abscess of Esophagus
530.20	Ulcer of Esophagus without Bleeding
530.21	Ulcer of Esophagus with Bleeding
530.85	Barrett's Esophagus
537.82	Angiodysplasia of Stomach and Duodenum without Mention of
	Hemorrhage
537.83	Angiodysplasia of Stomach and Duodenum with Hemorrhage
577.1	Chronic Pancreatitis
578.9	Gastrointestinal Hemorrhage
New Allowable Diagnosis Codes	
530.13	Eosinophilic Esophagitis
530.84	Tracheoesophageal Fistula
750.3-750.9	Congenital Tracheoesophageal Fistula
535.1-535.9	Atrophic Gastritis with Hemorrhage
535.7X	Eosinophilic Gastritis
538	Gastrointestinal Mucositis (Ulcerative)
No Longer Allowable Diagnosis Code	
536.8	Gastric Hyperacidity

Edits on PPIs November 25, 2014 Page 2 of 2

The ICD-9-CM diagnosis code must be documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

## Therapeutic Duplication Override

Pharmacy claims for Proton Pump Inhibitors (PPIs) will <u>not</u> accept a pharmacist override for a therapeutic duplication (TD, MO, 1G). There are no longer override provisions through the Point of Sale (POS) system using NCPDP service codes.

Compliance associated with program policy will be verified through our Louisiana Medicaid Pharmacy Compliance Audit Program.

Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

If you have questions about the contents of this memo, you may contact the Pharmacy Help Desk at (800) 437-9101, send a fax to (225) 342-1980, or refer to www.lamedicaid.com.

#### MCJ/MBW/ESF

c: Bayou Health Plans

Dr. James Hussey

Dr. Rebekah Gee

Dr. Rochelle Dunham

Magellan of Louisiana (Managed Care)

Melwyn B. Wendt

Molina